Key result
Combined administration of trandolapril and LU 135252 in rats with chronic heart failure decreased LV systolic and end-diastolic pressures by 32% and 80% but did not additionally improve survival.
Why the study?
Does the combination of an endothelin-A receptor antagonist and an ACE inhibitor improve hemodynamics and survival in a rat model of chronic heart failure?
Population
Rats with chronic heart failure induced by coronary artery ligation
Comparison
Trandolapril, LU 135252, or their combination… vs Vehicle
Design
Preclinical
Follow-up
3 or 9 months
Authors
Loading...
Combination improves hemodynamics without added survival benefit in rat HF; hypothesis-generating and should not yet change practice.
Does the combination of an endothelin-A receptor antagonist and an ACE inhibitor improve hemodynamics and survival in a rat model of chronic heart failure?
In a rat model of heart failure, combining an endothelin-A antagonist with an ACE inhibitor improves hemodynamics more than either drug alone but does not further improve long-term survival.
Mulder et al. (2002) studied Chronic Heart Failure. Trandolapril and LU 135252 combination vs. Vehicle, trandolapril alone, or LU 135252 alone was evaluated on LV systolic and end-diastolic pressures and long-term survival. Combined administration of trandolapril and LU 135252 in rats with chronic heart failure decreased LV systolic and end-diastolic pressures by 32% and 80% but did not additionally improve survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: